8-K: Axsome Therapeutics Reports Strong Q3 2024 Revenue Growth and Pipeline Progress

Axsome Therapeutics announced a robust third quarter with significant revenue growth and advancements in its clinical pipeline, including upcoming data readouts and regulatory submissions.

Summary

• Axsome Therapeutics reported a strong third quarter in 2024, with total net product revenue reaching $104.8 million, an 81% increase year-over-year.
• Auvelity net product sales were $80.4 million, showing a 113% year-over-year growth, while Sunosi net product revenue was $24.4 million, a 21% increase year-over-year.
• The company is planning a second expansion of its Auvelity sales force in the first quarter of 2025 due to strong demand.
• The FDA has accepted the NDA resubmission for AXS-07 for migraine treatment, with a PDUFA goal date of January 31, 2025.
• Topline results from several Phase 3 trials, including AXS-05 in Alzheimer's agitation and AXS-12 in narcolepsy, are expected in the fourth quarter of 2024.
• Topline results for solriamfetol trials in ADHD and MDD are anticipated in the first quarter of 2025.
• The company expects to submit an NDA for AXS-14 for fibromyalgia in November 2024.
• Axsome believes its current cash is sufficient to fund operations into cash flow positivity based on the current operating plan.
• The company's cash and cash equivalents totaled $327.3 million as of September 30, 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, pipeline advancements, and sufficient cash runway. The company is executing well on its commercial and development plans, with multiple catalysts expected in the near term. However, the net loss and increased expenses temper the overall sentiment slightly.

Positives

• Axsome experienced significant revenue growth in Q3 2024, driven by strong sales of Auvelity and Sunosi.
• Auvelity sales showed exceptional growth, indicating strong market acceptance and demand.
• The company has a robust pipeline with multiple late-stage clinical trials progressing towards key milestones.
• The FDA acceptance of the AXS-07 NDA resubmission and the upcoming PDUFA date are positive regulatory developments.
• Axsome has sufficient cash to fund operations into cash flow positivity, based on the current operating plan.
• Payer coverage for Auvelity and Sunosi is strong, with 78% and 83% of covered lives, respectively.
• The company is expanding its sales force to meet the growing demand for Auvelity.

Negatives

• The company reported a net loss of $64.6 million for the third quarter of 2024, although this included $40.9 million in non-cash charges.
• Research and development expenses increased to $45.4 million in Q3 2024, compared to $28.8 million in the same period in 2023.
• Selling, general, and administrative expenses also increased to $95.6 million in Q3 2024, compared to $83.2 million in the same period in 2023.
• Cash and cash equivalents decreased from $386.2 million at the end of 2023 to $327.3 million as of September 30, 2024.

Risks

• The company's future success depends on the continued commercial success of Auvelity and Sunosi.
• There are risks associated with the success, timing, and cost of ongoing and anticipated clinical trials.
• The company's ability to obtain and maintain regulatory approvals for its product candidates is not guaranteed.
• There are risks related to intellectual property protection and potential litigation.
• The company's ability to convert sales to recognized revenue and maintain a favorable gross to net sales is a risk.
• Unforeseen circumstances or disruptions to normal business operations could impact the company's performance.

Future Outlook

Axsome believes its current cash is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan. The company anticipates multiple clinical trial readouts and regulatory submissions in the near term, with potential new product launches through 2027.

Management Comments

• In the third quarter, we continued our strong commercial performance and advanced our innovative, industry-leading, late-stage development pipeline towards important near-term milestones, said Herriot Tabuteau, MD, Chief Executive Officer.
• In response to continued strong demand growth, a second expansion of the Auvelity sales force is planned for the first quarter of 2025.
• With the January 31, 2025, PDUFA date for our AXS-07 product candidate for migraine fast approaching, commercial preparations are underway for a timely and successful launch, if approved.
• We expect a busy end to the year with several clinical catalysts anticipated, including a planned simultaneous release of topline results from the ongoing Phase 3 ADVANCE-2 and ACCORD-2 trials of AXS-05 in Alzheimers disease agitation in the fourth quarter.
• Our growth as an organization positions us well to potentially deliver multiple innovative new medicines to the millions of individuals living with central nervous system disorders in the U.S.
• Importantly, we have the resources in hand to execute our operating plans and create substantial value for shareholders.

Industry Context

Axsome's focus on central nervous system disorders aligns with a growing need for innovative treatments in this space. The company's pipeline addresses several unmet needs, including Alzheimer's agitation, migraine, narcolepsy, and fibromyalgia. The strong commercial performance of Auvelity and Sunosi indicates a positive market reception for novel CNS therapies.

Comparison to Industry Standards

• Axsome's 113% year-over-year growth in Auvelity sales significantly outpaces the average growth rate for pharmaceutical products in the CNS space, which typically ranges from 5-20% for established products.
• The company's pipeline includes multiple Phase 3 trials, which is comparable to other mid-sized biopharmaceutical companies focused on CNS disorders, such as Sage Therapeutics and Intra-Cellular Therapies.
• The PDUFA goal date for AXS-07 is a critical milestone, and its success will be compared to other recent migraine drug launches, such as Nurtec ODT and Ubrelvy, in terms of market uptake and patient satisfaction.
• The planned expansion of the Auvelity sales force is a strategic move similar to what other companies do when they see strong demand for a new product, such as what happened with the launch of Trintellix by Lundbeck and Takeda.
• Axsome's focus on novel mechanisms of action, such as the NMDA receptor antagonism of AXS-05, is a differentiator compared to companies that focus on more traditional approaches, such as SSRIs for depression.

Legal Proceedings

• The patent litigation with Sandoz Inc. related to Sunosi was dismissed following Sandoz's withdrawal of its ANDA for a generic equivalent of Sunosi.

Stakeholder Impact

• Shareholders are likely to react positively to the strong revenue growth and pipeline progress.
• Employees may benefit from the company's growth and expansion.
• Patients may benefit from the potential approval and launch of new treatments for CNS disorders.
• Customers (physicians and pharmacies) will see increased availability of Axsome's products.
• Suppliers and creditors will benefit from the company's financial stability and growth.

Next Steps

• The company will submit an NDA for AXS-14 for fibromyalgia in November 2024.
• Topline results from multiple Phase 3 trials are expected in the fourth quarter of 2024 and the first quarter of 2025.
• The company will continue commercial preparations for the potential launch of AXS-07 for migraine.
• The company will expand its Auvelity sales force in the first quarter of 2025.
• The company will initiate a pivotal Phase 2/3 trial of AXS-05 in smoking cessation in 2025.

Key Dates

Keywords

Axsome Therapeutics, Auvelity, Sunosi, AXS-05, AXS-07, AXS-12, AXS-14, solriamfetol, Alzheimer's disease, migraine, narcolepsy, fibromyalgia, ADHD, MDD, CNS disorders, clinical trials, FDA, PDUFA, pharmaceuticals